Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357853 | 0.85 | HPGD (0.50) | SSTR4 | |
| SCHEMBL14391516 | 0.85 | HPGD (0.50) | SSTR4 | |
| SCHEMBL358475 | 0.83 | NAMPT (0.64) | NAMPTEPHX1MAPT | |
| SCHEMBL359825 | 0.79 | KDM5A (0.44) | NAMPTSSTR4MAPK1SSTR1 | |
| SCHEMBL4975797 | 0.77 | ALDH1A1 (0.52) | — | |
| SCHEMBL359497 | 0.77 | ALDH1A1 (0.51) | NAMPTCYP2C19 | |
| SCHEMBL13242298 | 0.75 | DRD4 (0.66) | NAMPTEPHX1SSTR4SSTR1 | |
| SCHEMBL1908693 | 0.74 | TACR1 (0.46) | NAMPTSSTR4MMP13MAPK1 | |
| SCHEMBL1908655 | 0.74 | EPHX1 (0.61) | NAMPTEPHX1MAPK1 | |
| SCHEMBL1908718 | 0.73 | DRD2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | NAMPT 1763/4885EPHX1 1339/4885MAPT 3049/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | NAMPT 2644/4885EPHX1 1066/4885MAPT 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.